COVID-19 Vaccine Responses in PIDD Subjects
Running, not enrolling
Conditions studied: X-linked Agammaglobulinemia, XLA, Primary Immune Deficiency, CVID, Common Variable Immunodeficiency, Primary Antibody Deficiencies, Secondary Hypogammaglobulinemia
In brief
The goal of our study is to assess the cellular immune responses of participants with antibody deficiency disease before and after immunization with SARS-CoV-2 mRNA vaccines.
Key facts
- Study ID
- NCT05321407
- Run by
- Duke University
- People needed
- 100
- Starts
- 2021-09-30
- Expected to finish
- 2026-07-31
- Last updated by the study team
- 2025-06-03
Who can join
Age: 1 and older. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- Diagnosis of antibody deficiency with confirmatory lab or genetic testing
- Stable on immunoglobulin replacement therapy
- Age >6 months and able to provide consent, or assent with parental consent if <18 years
- Willing and able to receive the Pfizer BioNTech BNT162b2 mRNA or the Moderna mRNA-1273 vaccines
You may not qualify if…
- (1) History of other chronic disease with depressed immune function or immune suppressive medication
Where it is running
- University of South Florida — St. Petersburg, Florida, United States
- University of North Carolina, Chapel Hill — Chapel Hill, North Carolina, United States
- Duke University — Durham, North Carolina, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.